Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Wild thyme (Thymus serpyllum) is closely related to common thyme and shares its thymol and carvacrol content. Used for respiratory support, antimicrobial effects, and as a traditional antitussive. Generally very well tolerated. Avoid high-dose concentrated extract in pregnancy (uterotonic at pharmacological doses). May mildly enhance anticoagulant effects at very high doses. Standard supplemental and culinary doses have an excellent safety profile.
Biological and Chemical Classification
- Scientific Name
- Thymus serpyllum
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Wild Thyme indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:10
Evidence Distribution
-
Observational / other LOW evidence YELLOWComparative chemical and biological study of essential oils and n-hexane extracts of Thymus vulgaris and Thymus serpyllum (Lamiaceae). ↗AbdelRazek MMM et al.. Comparative chemical and biological study of essential oils and n-hexane extracts of Thymus vulgaris and Thymus serpyllum (Lamiaceae).. Sci Rep. 2026. PMID:41545367.PMID 41545367 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41545367/
-
Observational / other LOW evidence YELLOWIn Vitro Antibacterial Potential of Pinus nigra-Thymus serpyllum Essential Oil and Antibiotic Combinations. ↗Kahya SE et al.. In Vitro Antibacterial Potential of Pinus nigra-Thymus serpyllum Essential Oil and Antibiotic Combinations.. ACS Omega. 2025. PMID:41476549.PMID 41476549 ↗Journal ACS OmegaYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41476549/
-
Observational / other LOW evidence YELLOWEvaluation of the Antiangiogenic Activity of Thymus serpyllum Aerial Parts Extracts Using the Chorioallantoic Membrane Assay. ↗Latif F et al.. Evaluation of the Antiangiogenic Activity of Thymus serpyllum Aerial Parts Extracts Using the Chorioallantoic Membrane Assay.. Cureus. 2025. PMID:41425679.PMID 41425679 ↗Journal CureusYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41425679/
-
Observational / other LOW evidence YELLOWDrought, herbivory and combined stress caused treatment-specific changes in phytohormones, but species-specific changes in secondary metabolite profiles in thyme. ↗Alipour M et al.. Drought, herbivory and combined stress caused treatment-specific changes in phytohormones, but species-specific changes in secondary metabolite profiles in thyme.. Front Plant Sci. 2025. PMID:41404140.PMID 41404140 ↗Journal Front Plant SciYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41404140/
-
Observational / other LOW evidence YELLOWHow a Green Roof Becomes Biodiverse: Vegetation Analysis on a Green Roof with no Maintenance in Rome (Italy). ↗Bellini A et al.. How a Green Roof Becomes Biodiverse: Vegetation Analysis on a Green Roof with no Maintenance in Rome (Italy).. Plants (Basel). 2025. PMID:41157737.PMID 41157737 ↗Journal Plants (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41157737/
-
Observational / other LOW evidence YELLOWCytotoxic Effects of Thymus serpyllum L. and Mentha u00d7 piperita L. Essential Oils on Basal Cell Carcinoma-An In Vitro Study. ↗Milosevic Markovic M et al.. Cytotoxic Effects of Thymus serpyllum L. and Mentha u00d7 piperita L. Essential Oils on Basal Cell Carcinoma-An In Vitro Study.. Life (Basel). 2025. PMID:40868944.PMID 40868944 ↗Journal Life (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40868944/
-
Observational / other LOW evidence YELLOWLiposome-Based Encapsulation of Extract from Wild Thyme (Thymus serpyllum L.) Tea Processing Residues for Delivery of Polyphenols. ↗Jovanoviu0107 AA et al.. Liposome-Based Encapsulation of Extract from Wild Thyme (Thymus serpyllum L.) Tea Processing Residues for Delivery of Polyphenols.. Foods. 2025. PMID:40807563.PMID 40807563 ↗Journal FoodsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40807563/
-
Observational / other LOW evidence YELLOWPhenolic composition, cholinesterase inhibition, and in silico study of traditional medicinal plants from Bosnia And Herzegovina. ↗Ibragic S et al.. Phenolic composition, cholinesterase inhibition, and in silico study of traditional medicinal plants from Bosnia And Herzegovina.. Nat Prod Res. 2025. PMID:40753589.PMID 40753589 ↗Journal Nat Prod ResYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40753589/
-
Observational / other LOW evidence YELLOWSafety and efficacy of a feed additive consisting of a tincture derived from the leaves or aerial parts of Thymus serpyllum L.… ↗Villa RE et al.. Safety and efficacy of a feed additive consisting of a tincture derived from the leaves or aerial parts of Thymus serpyllum L. (wild thyme tincture) for use in all animal species (FEFANA asbl).. EFSA J. 2025. PMID:40741370.PMID 40741370 ↗Journal EFSA JYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40741370/
-
Observational / other LOW evidence YELLOWThymus serpyllum extract exerts anticancer activities against colorectal cancer by modulating metastasis, cell cycle arrest, and apoptosis. ↗Yao CY et al.. Thymus serpyllum extract exerts anticancer activities against colorectal cancer by modulating metastasis, cell cycle arrest, and apoptosis.. Mol Biol Rep. 2025. PMID:40679559.PMID 40679559 ↗Journal Mol Biol RepYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40679559/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Wild Thyme. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Wild Thyme
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.